Lantheus to Host Q2 2026 Earnings Call and Webcast on Aug 6
Lantheus Holdings, Inc. will host its Q2 2026 earnings call on August 6, 2026, at 8:00 a.m. ET. The webcast will feature financial results and business updates. Investors can register via the company’s investor relations website, with replays available shortly after the event.
*this image is generated using AI for illustrative purposes only.
Lantheus Holdings, Inc. (NASDAQ: LNTH) will host a conference call and webcast on August 6, 2026, at 8:00 a.m. Eastern Time to discuss its financial results and provide a business update for the second quarter of 2026. The event offers investors direct access to management’s commentary on the company’s performance during the period, with live participation available through an online registration portal.
To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events . Lantheus encourages participants to register fifteen minutes ahead of the scheduled start time to avoid delays. A replay of the webcast will be available approximately two hours after completion and will be archived on the same web page for at least 30 days.
Event Details
| Detail | Information |
|---|---|
| Date | August 6, 2026 |
| Time | 8:00 a.m. Eastern Time |
| Format | Conference Call and Webcast |
| Replay Availability | ~2 hours post-event, archived for 30 days |
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Bedford, Massachusetts, with offices in New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years.
Contacts
For investor relations inquiries:
- Mark Kinarney, Vice President, Investor Relations
- Phone: 978-671-8842
- Email: ir@lantheus.com
For media inquiries:
- Melissa Downs, Executive Director, External Communications
- Phone: 646-975-2533
- Email: media@lantheus.com
How might Lantheus's Q2 2026 financial results reflect the commercial adoption rates of its newer radiopharmaceutical therapies in the oncology and cardiology segments?
What strategic implications could the upcoming business update have for Lantheus's pipeline development, particularly regarding its next-generation imaging agents?
How is the company addressing potential supply chain constraints or regulatory hurdles in its international markets (Canada, Germany, Sweden, Switzerland, UK) during this quarter?
19
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
